These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11465305)

  • 1. Lifestyle drugs: determining their value and who should pay.
    Mitrany D
    Pharmacoeconomics; 2001; 19(5 Pt 1):441-8. PubMed ID: 11465305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
    Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S
    Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of US Drug Costs Relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010-2016.
    McRae J; Vogenberg FR; Beaty SW; Mearns E; Varga S; Pizzi L
    Pharmacoeconomics; 2017 Feb; 35(2):215-223. PubMed ID: 27798809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifestyle drugs in old age--a mini-review.
    Harth W; Seikowski K; Hermes B
    Gerontology; 2009; 55(1):13-20. PubMed ID: 19001804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-to-consumer promotion of prescription drugs. Economic implications for patients, payers and providers.
    Findlay SD
    Pharmacoeconomics; 2001; 19(2):109-19. PubMed ID: 11284378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New lifestyle drugs and somatoform disorders in dermatology.
    Harth W; Seikowski K; Hermes B; Gieler U
    J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):141-9. PubMed ID: 18081754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifestyle treatments in cystic fibrosis: The NHS should pay.
    Ketchell RI
    Paediatr Respir Rev; 2016 Aug; 20 Suppl():12-4. PubMed ID: 27373763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual responsibility and health-risk behaviour: a contingent valuation study from the ex ante societal perspective.
    van der Star SM; van den Berg B
    Health Policy; 2011 Aug; 101(3):300-11. PubMed ID: 21168930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bioethics and pharmacoeconomics: a difficult balance].
    Felicetti V; Cristina G; Cifaldi L
    Clin Ter; 2008; 159(1):29-32. PubMed ID: 18399259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of market-based 'reform' on cultural values in health care.
    Curtin LL
    Semin Nurse Manag; 1999 Dec; 7(4):198-202. PubMed ID: 11013589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anatomy of health care in the United States.
    Moses H; Matheson DH; Dorsey ER; George BP; Sadoff D; Yoshimura S
    JAMA; 2013 Nov; 310(18):1947-63. PubMed ID: 24219951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The analysis of physicians' work: announcing the end of attempts at in vitro fertilization].
    Santiago-Delefosse M; Cahen F; Coeffin-Driol C
    Encephale; 2003; 29(4 Pt 1):293-305. PubMed ID: 14615699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The drugs don't sell: DIY heart health and the over-the-counter statin experience.
    Will CM; Weiner K
    Soc Sci Med; 2015 Apr; 131():280-8. PubMed ID: 24954520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reimbursement and pharmacoeconomic perspectives in biotechnology.
    Bleecker GC
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S27-30. PubMed ID: 8362887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.